Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer.
anaplastic thyroid cancer
iodine resistance
novel therapeutic
radioactive iodine resistance
thyroid cancer
well differentiated thyroid cancer
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2021
2021
Historique:
received:
04
06
2021
accepted:
24
06
2021
entrez:
2
8
2021
pubmed:
3
8
2021
medline:
15
2
2022
Statut:
epublish
Résumé
Iodine-resistant cancers account for the vast majority of thyroid related mortality and, until recently, there were limited therapeutic options. However, over the last decade our understanding of the molecular foundation of thyroid function and carcinogenesis has driven the development of many novel therapeutics. These include FDA approved tyrosine kinase inhibitors and small molecular inhibitors of VEGFR, BRAF, MEK, NTRK and RET, which collectively have significantly changed the prognostic outlook for this patient population. Some therapeutics can re-sensitize de-differentiated cancers to iodine, allowing for radioactive iodine treatment and improved disease control. Remarkably, there is now an FDA approved treatment for BRAF-mutated patients with anaplastic thyroid cancer, previously considered invariably and rapidly fatal. The treatment landscape for iodine-resistant thyroid cancer is changing rapidly with many new targets, therapeutics, clinical trials, and approved treatments. We provide an up-to-date review of novel therapeutic options in the treatment of iodine-resistant thyroid cancer.
Identifiants
pubmed: 34335481
doi: 10.3389/fendo.2021.720723
pmc: PMC8321684
doi:
Substances chimiques
Iodine Radioisotopes
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
720723Informations de copyright
Copyright © 2021 Fullmer, Cabanillas and Zafereo.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cell. 2014 Oct 23;159(3):676-90
pubmed: 25417114
Thyroid. 2018 Jul;28(7):945-951
pubmed: 29742974
Lancet Oncol. 2016 Sep;17(9):1272-82
pubmed: 27460442
J Clin Oncol. 2018 Jan 1;36(1):7-13
pubmed: 29072975
Int J Mol Sci. 2016 Dec 06;17(12):
pubmed: 27929428
Eur J Endocrinol. 2009 Dec;161(6):923-31
pubmed: 19773371
Oncotarget. 2016 May 24;7(21):30907-23
pubmed: 27127178
J Clin Invest. 2011 Dec;121(12):4700-11
pubmed: 22105174
J Clin Endocrinol Metab. 1995 Jul;80(7):2041-5
pubmed: 7608252
BMC Cancer. 2019 Dec 12;19(1):1209
pubmed: 31830943
Mol Imaging Radionucl Ther. 2016 Jan 5;26(Suppl 1):80-86
pubmed: 28117292
Endocrine. 2019 Apr;64(1):122-129
pubmed: 30762153
JAMA Oncol. 2017 Feb 1;3(2):202-208
pubmed: 27581851
J Clin Endocrinol Metab. 2018 Oct 1;103(10):3698-3705
pubmed: 30032208
Cancers (Basel). 2019 Sep 17;11(9):
pubmed: 31533238
Curr Cancer Drug Targets. 2010 Mar;10(2):242-67
pubmed: 20201784
Cancers (Basel). 2019 Sep 18;11(9):
pubmed: 31540406
N Engl J Med. 2019 Aug 15;381(7):626-636
pubmed: 31166680
J Clin Invest. 2016 Mar 1;126(3):1052-66
pubmed: 26878173
J Clin Endocrinol Metab. 2014 May;99(5):1687-93
pubmed: 24606083
Thyroid. 2019 Aug;29(8):1036-1043
pubmed: 31319771
Clin Cancer Res. 2007 Feb 15;13(4):1341-9
pubmed: 17317846
J Korean Med Sci. 2018 Jan 24;33(27):e75
pubmed: 29962924
Clin Endocrinol (Oxf). 2017 Jan;86(1):128-133
pubmed: 27392538
Ther Adv Med Oncol. 2015 Mar;7(2):122-36
pubmed: 25755684
Thyroid. 2019 Nov;29(11):1615-1622
pubmed: 31595822
Clin Cancer Res. 2015 Mar 1;21(5):1028-35
pubmed: 25549723
Histopathology. 2017 Sep;71(3):357-365
pubmed: 28383817
Thyroid. 2021 Apr;31(4):607-615
pubmed: 32907500
JAMA Oncol. 2018 Sep 1;4(9):1237-1244
pubmed: 29902298
Lancet Oncol. 2020 Feb;21(2):271-282
pubmed: 31838007
Cancer Biother Radiopharm. 2007 Apr;22(2):250-5
pubmed: 17600472
Oncogene. 2000 Feb 17;19(7):924-32
pubmed: 10702801
Mol Cancer. 2018 Feb 19;17(1):51
pubmed: 29455653
Sci Rep. 2019 Apr 1;9(1):5404
pubmed: 30931962
Endocr Relat Cancer. 2014 Jan 30;21(2):161-73
pubmed: 24243688
Drug Des Devel Ther. 2016 Mar 11;10:1119-31
pubmed: 27042004
JAMA Oncol. 2020 Sep 1;6(9):1397-1404
pubmed: 32761153
Thyroid. 2009 Sep;19(9):953-6
pubmed: 19678746
Clin Cancer Res. 2018 Apr 1;24(7):1546-1553
pubmed: 29301825
Endocr Rev. 2019 Dec 1;40(6):1573-1604
pubmed: 31322645
Oncotarget. 2016 May 31;7(22):32318-28
pubmed: 27086918
Thyroid. 2012 Sep;22(9):884-9
pubmed: 22827579
Oncol Rep. 2015 Nov;34(5):2319-24
pubmed: 26324075
Nat Rev Cancer. 2008 Aug;8(8):592-603
pubmed: 18650835
J Clin Endocrinol Metab. 2013 May;98(5):E829-36
pubmed: 23533233
Thyroid. 2014 Apr;24(4):715-26
pubmed: 24102584
J Clin Endocrinol Metab. 2014 Jun;99(6):2086-94
pubmed: 24628550
J Natl Compr Canc Netw. 2019 May 1;17(5):409-413
pubmed: 31085763
J Clin Oncol. 2017 Oct 10;35(29):3315-3321
pubmed: 28817373
Lancet Oncol. 2012 Sep;13(9):897-905
pubmed: 22898678
J Clin Oncol. 2020 Aug 10;38(23):2620-2627
pubmed: 32364844
Thyroid. 2015 Oct;25(10):1106-14
pubmed: 26148759
BMC Cancer. 2019 Mar 4;19(1):196
pubmed: 30832606
Am J Med Sci. 2018 Aug;356(2):130-134
pubmed: 30219154
Head Neck Pathol. 2020 Dec;14(4):1067-1079
pubmed: 32358715
N Engl J Med. 2018 Feb 22;378(8):731-739
pubmed: 29466156
Thyroid. 2020 Sep;30(9):1288-1296
pubmed: 32216548
Cancer Cytopathol. 2018 Jun;126(6):406-413
pubmed: 29579361
Cancer Discov. 2013 May;3(5):520-33
pubmed: 23365119
EBioMedicine. 2017 Apr;18:50-55
pubmed: 28363612
Cancers (Basel). 2020 Jul 29;12(8):
pubmed: 32751138
Eur J Cancer. 2017 May;76:110-117
pubmed: 28301826
Cancers (Basel). 2020 Aug 04;12(8):
pubmed: 32759760
Anticancer Res. 2019 Mar;39(3):1119-1127
pubmed: 30842140
Curr Treat Options Oncol. 2016 Jun;17(6):30
pubmed: 27139457
Oncol Lett. 2018 Jun;15(6):9174-9182
pubmed: 29805648
J Clin Endocrinol Metab. 2006 Aug;91(8):2892-9
pubmed: 16684830
Endocr Relat Cancer. 2018 Jun;25(6):699-704
pubmed: 29752332
Lancet. 2014 Jul 26;384(9940):319-28
pubmed: 24768112
Ann Oncol. 2019 Nov 1;30(11):1848
pubmed: 31406976
Am J Transl Res. 2020 Mar 15;12(3):974-988
pubmed: 32269728
N Engl J Med. 2015 Feb 12;372(7):621-30
pubmed: 25671254
Cancer Chemother Pharmacol. 2014 Dec;74(6):1261-70
pubmed: 25315258
Oncol Lett. 2020 Jan;19(1):631-640
pubmed: 31897179
Cancer Manag Res. 2015 Aug 19;7:265-78
pubmed: 26316818
Expert Rev Anticancer Ther. 2016 Dec;16(12):1303-1309
pubmed: 27734713
Eur J Clin Pharmacol. 2020 Aug;76(8):1125-1133
pubmed: 32382947
Ann Oncol. 2013 Dec;24(12):3089-94
pubmed: 24050953
Thyroid. 2018 Nov;28(11):1455-1461
pubmed: 30142994
Semin Oncol. 2019 Feb;46(1):57-64
pubmed: 30685073
Chonnam Med J. 2019 Sep;55(3):127-135
pubmed: 31598469
Clin Nucl Med. 2018 Sep;43(9):641-647
pubmed: 30015659
Thyroid. 2013 May;23(5):593-9
pubmed: 23186033
J Biol Chem. 2004 Jan 30;279(5):3439-46
pubmed: 14623893
Ann Surg. 2007 Sep;246(3):466-70; discussion 470-1
pubmed: 17717450
J Immunother Cancer. 2018 Jul 11;6(1):68
pubmed: 29996921
J Clin Oncol. 2010 Jul 1;28(19):e312-3
pubmed: 20516434
J Endocrinol. 2010 Jul;206(1):113-20
pubmed: 20392814
J Transl Med. 2016 Jul 07;14(1):204
pubmed: 27387551
N Engl J Med. 2013 Feb 14;368(7):623-32
pubmed: 23406027
J Clin Oncol. 2015 Jul 10;33(20):e84-7
pubmed: 24687827
Lancet Oncol. 2010 Oct;11(10):962-72
pubmed: 20851682
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
N Engl J Med. 2020 Oct 22;383(17):1686-1687
pubmed: 33085869
Curr Pharm Des. 2016;22(39):5915-5926
pubmed: 27306093
Eur J Endocrinol. 2003 Apr;148(4):395-402
pubmed: 12656659
Thyroid. 2021 Mar;31(3):337-386
pubmed: 33728999
Thyroid. 2017 May;27(5):672-681
pubmed: 28068873
Lancet Oncol. 2020 Apr;21(4):531-540
pubmed: 32105622
N Engl J Med. 2012 Nov;367(18):1694-703
pubmed: 23020132
Thyroid. 2015 Jan;25(1):71-7
pubmed: 25285888
Clin Cancer Res. 2012 Apr 1;18(7):2056-65
pubmed: 22241789
Thyroid. 2020 Feb;30(2):343-344
pubmed: 31892283
Endocrine. 2017 Apr;56(1):121-128
pubmed: 28155175
N Engl J Med. 2020 Aug 27;383(9):825-835
pubmed: 32846061
Thyroid. 2019 Apr;29(4):461-470
pubmed: 30900516
Clin Cancer Res. 2019 Sep 15;25(18):5475-5484
pubmed: 31186313
Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4233-8
pubmed: 24613930